Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) Current Assets (2016 - 2025)

Tvardi Therapeutics' Current Assets history spans 13 years, with the latest figure at $31.5 million for Q4 2025.

  • On a quarterly basis, Current Assets changed 0.47% to $31.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $31.5 million, a 0.47% change, with the full-year FY2025 number at $31.5 million, changed 0.47% from a year prior.
  • Current Assets hit $31.5 million in Q4 2025 for Tvardi Therapeutics, down from $38.4 million in the prior quarter.
  • Over the last five years, Current Assets for TVRD hit a ceiling of $188.4 million in Q1 2021 and a floor of $31.5 million in Q4 2025.
  • Historically, Current Assets has averaged $116.0 million across 5 years, with a median of $124.7 million in 2023.
  • Biggest five-year swings in Current Assets: soared 41.97% in 2021 and later plummeted 72.72% in 2024.
  • Tracing TVRD's Current Assets over 5 years: stood at $173.3 million in 2021, then fell by 2.53% to $168.9 million in 2022, then plummeted by 31.23% to $116.2 million in 2023, then plummeted by 72.72% to $31.7 million in 2024, then fell by 0.47% to $31.5 million in 2025.
  • Business Quant data shows Current Assets for TVRD at $31.5 million in Q4 2025, $38.4 million in Q3 2025, and $43.1 million in Q2 2025.